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ABSTRACT 
Background: Despite the significant morbidity and mortality associated with pneumococcal 
disease, the national vaccination rates for pneumococcal vaccine for patients 65 years and older 
fall below the Healthy People goal of 2020. In recent years, there is a growing trend in the use of 
retail health clinics in the country. These retail health clinics can be an avenue to close the gap in 
the delivery of pneumococcal vaccination. The purpose of this project is to assess the baseline 
knowledge of retail health providers and their perception of barriers to pneumonia vaccinations. 
In addition, a program called The Four Pillars on Immunization Toolkit was implemented to 
increase pneumococcal immunization rates in a retail health clinic. 
Purpose: This project explored the baseline knowledge of the providers and the perceived 
barriers regarding the delivery of pneumococcal vaccination. Furthermore, The Four Pillars on 
Immunization Toolkit was utilized to increase immunization in a retail health clinic.  
Methods: The baseline knowledge and perception of barriers to delivering the pneumonia 
vaccination was assessed via an online survey. To increase the pneumococcal vaccination, the 
participants were educated on the Four Pillars on Immunization Toolkit before actual 
implementation. 
Results: The scores on the knowledge section of the survey ranged from 9% to 81%. These 
results indicated that providers working in the retail health setting could benefit from 
pneumococcal vaccination education. The results on the perception of barriers showed that 
providers working the retail clinics face barriers that prevent the recommendation or the giving 
of pneumococcal vaccination. In addition, the use of the Four Pillars on Immunization toolkit 
indicated a 10 % increase in pneumococcal vaccination rate when compared to the previous year. 
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Conclusion: The result indicated that providers working in the retail clinic are generally 
knowledgeable about pneumonia vaccination; however, there is a gap noted on certain 
knowledge questions. In addition, providers noted barriers that prevent the recommendation or 
the giving of the pneumonia vaccination in this setting. The results suggested the use of the Four 
Pillars on Immunization Toolkit could be used as a tool in a retail clinic to improve delivery of 
important immunizations. 
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INTRODUCTION 
Despite being proven effective, adult vaccinations are still underutilized. Adults who are 
not immunized are at risk of illness, hospitalization, and even death from vaccine-preventable 
diseases (Center for Disease Control and Prevention, 2016). Immunization is an essential part of 
preventative health services to improve and eradicate diseases. The use of vaccines to help 
eliminate diseases is one of the biggest successes of modern science. Vaccinations currently 
prevent 2-3 million deaths worldwide per year, and vaccinations are considered one of the most 
cost-effective public health interventions (World Health Organization, 2018). In the United 
States, the Center for Disease Control and Prevention (CDC) estimated that vaccinations 
prevented more than 21 million hospitalizations and 732 deaths among children born in the last 
20 years (CDC, 2014). Despite the proven efficacy of vaccinations, adult vaccination rates in the 
United States are consistently lower than Healthy People 2020 goals (Equils et al., 2018). 
Healthy People 2020 program is a nationwide program that provides a 10-year goal to improve 
the health of the people (Office of Disease Prevention and Health Promotion, 2019). Because of 
the low utilization rates for adult vaccinations in the United States, there are still individuals who 
die from vaccine-preventable diseases. These deaths could be prevented if affected people 
choose to be vaccinated. 
Many vaccinations for adults are recommended and available in the United States. The 
United States Advisory Committee on Immunization Practices (ACIP), established in 1964 by 
the U.S. Surgeon General, provides immunization recommendations to the CDC (Smith, 2010). 
Category ‘A’ recommendations are for routine use in the general population, and Category ‘B’ 
recommendations are for vaccines recommended by a medical provider based on their medical 
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judgment (Tan, 2015). The ACIP currently recommends immunizing adults against 15 diseases 
known to commonly cause significant illnesses. Criteria for administration consider age and risk 
factors. These vaccines are targeted to prevent illnesses such as influenza, diphtheria, tetanus, 
pertussis, varicella, human papillomavirus, zoster, mumps, measles, rubella, pneumococcal 
disease, meningococcal disease, hepatitis A, hepatitis B, and haemophilus influenzae. These 
diseases remain a public health concern among the adult population because of low rates of 
immunization (Tan, 2015). 
Immunization rates among children are at or above 90% as recommended by the ACIP 
(Mellerson et al., 2018), but this success has not transpired to the adult population. For example, 
the immunization rate for pneumococcal vaccination among adults was only at 59.9%, which is 
significantly below the 90% goal set by Healthy People 2020 (Tan, 2015).  
Background Knowledge 
One of the 15 infectious diseases prevented through vaccination is streptococcus 
pneumonia (pneumococcus). This disease is still the leading cause of serious illness. Once 
infected with this organism, a person is at risk for bacteremia, meningitis, sinusitis, otitis media, 
and pneumonia. These diseases are the most common and preventable infectious diseases having 
a high rate of morbidity and fatality rate worldwide (Cilloniz, Amaro, & Torres, 2016). In 2013 
alone, there were approximately 3,700 deaths from pneumococcal meningitis and bacteremia 
(CDC, 2018). 
Another disease that can be prevented with pneumonia immunization is pneumococcal 
pneumonia. This is by far the most common form of pneumococcal disease in adults, which 
affects approximately 900,000 Americans each year. In addition, about 5% to 7% of people who 
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contract the disease do not survive. Further, approximately 400,000 individuals are hospitalized 
annually from pneumococcal pneumonia (CDC, 2018).  
In 2014, the ACIP recommended the routine use of 13-valent pneumococcal conjugate 
vaccine (PCV13) or its brand name, Prevnar-13 and the 23-valent pneumococcal polysaccharide 
vaccine (PPSV23) also called the Pneumovax-23 among adults 65 years and older (CDC, 2019). 
On June 2019, the ACIP recommended the removal of routine use of PCV13 among patients 65 
years and older who do not have immunocompromising condition and recommended the 
decision to immunize is based on shared decision making by the patient and the provider (CDC, 
2019) .The recommendation to immunize patients 65 years and older with immunocompromising 
condition however, has not changed (CDC, 2019). 
Despite efforts to increase the rate for adult immunization against pneumococcal 
diseases, it is still far below the Healthy People 2020 goal of having 90% of adults 65 years and 
older being immunized with pneumonia vaccine. See Table 1 for estimations of adults who 
received the pneumonia vaccine (Ecklund, 2017). Efforts to increase pneumonia vaccination 
include educating the providers, who play a key role. Multiple studies have reported a provider's 
recommendation was the primary reason why a patient decided to get the immunization 
(Physicians Weekly, 2015). 
TABLE 1. Estimated proportion of U.S. adults ≥ 65 years old who received pneumococcal 
vaccines 2010-2014, National Health Interview Survey, United States. 
Pneumococcal Vaccination 
rate among U.S. adults > 65 
2010 2011 2012 2013 2014 
59.7 62.3 59.9 59.7 61.3 
Un-weighted sample size (2010-2014):34,640 (Williams et al., 2016) 
To estimate the number of Medicare beneficiaries who received the pneumococcal 
vaccination after the ACIP recommended the vaccine, the CDC (2018) analyzed the data 
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submitted for reimbursement to the Center for Medicaid and Medicare Services. The results in 
Figure 1 show claims from September 19, 2009 to September 18, 2017. Receipt of pneumonia 
vaccine claims for both Pneumovax 23 and Prevnar 13 among Medicare beneficiaries aged 65 
years and older ranged from 40% to 59.3% from periods ranging from September 2010 to 
September 2017. 
 
FIGURE 1. Proportion of Medicare beneficiaries aged ≥ 65 years old with claims submitted for 
pneumococcal vaccination-United States, September 2009-2017 (CDC, 2018). 
Economic Burden 
Ozawa et al. (2015) reported the economic burden for a vaccine-preventable disease is 
approximately 9 billion dollars. Of this amount, $5.9 billion was estimated to be related to 
inpatient treatment and $2.4 billion related to outpatient treatment. To put this number into 
perspective, the average cost for a hospitalized patient diagnosed with influenza is $5,770. For a 
patient diagnosed with invasive meningococcal disease, the average cost is $15,600 per 
hospitalization. The cost to treat pneumococcal diseases in 2015 was a staggering $1.86 billion. 
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Therefore, a need exists to increase adult pneumococcal vaccination rates to reduce the burden to 
the economy. 
In recent years, a new trend emerged and has become the latest model in the delivery of 
ambulatory care: retail health clinics (Wang et al., 2010). The number of retail clinics across the 
country has risen significantly from 130 retail clinics in 2006 to about 1,400 in 2012 (Martsolf et 
al., 2017). The current estimated number of retail clinics, according to Statistica (2018) is at 
2,800 across the United States. Retail clinics are located within 10 minutes from the majority of 
the urban population. With convenient hours and locations, retail health clinics are becoming 
accessible to most patients who seek convenient and affordable care (Martsolf et al., 2017). 
Patients who sought services at retail health clinics report retail health clinics are much more cost 
effective than emergency room visits. The locations are convenient and wait times are shorter, 
with proximity to workplaces (Wang et al., 2010). Nurse practitioners and physician assistants 
who provide episodic care to patients often staff retail clinics. Recent data shows patients are 
beginning to seek vaccinations and preventative health care at retail health clinic locations 
(Kaissi, 2015). In the year 2007, 2008 and 2010 there were 39.9%, 36.4%, and 42.0% 
vaccinations administered during visits to retail-based clinics. The pneumococcal vaccine was 
administered to 59,849 patients in 2009, which was about 3% of all vaccination visits. In general, 
the overall vaccination rates show an increase in the number of immunizations given in retail 
settings (Uscher-Pines, Harris & Burns, 2012). This trend suggests vaccinations in retail clinics 
can represent an avenue to reach immunization goals for Healthy People 2020.  
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To date, limited studies exist looking into retail health clinic providers’ knowledge and 
perceived barriers in vaccination delivery. There are also limited studies available on how to 
increase vaccination delivery in retail health clinics. 
Local Problem 
The number of cases of pneumonia increases during the flu season. The data from the 
2017-2018 influenza season indicates that 21,268 cases of influenza were reported in Arizona. 
Out of this number, there were 461 deaths related to pneumonia and influenza (Arizona 
Department of Health Services, 2018). For invasive streptococcus pneumonia alone, Maricopa 
county had 124 cases in 2017 and 173 cases in 2018 for patients 65 years old and older (Keenan, 
personal communication, July 2019). 
The Kaiser Family Foundation (2017) reported that 75.4% of adults aged 65 and over in 
Arizona received the pneumonia vaccine, which is a higher percentage than in other states in the 
USA. However, this rate still falls below the Healthy People 2020 goal. Among Medicare 
patients residing in Arizona, about 57.6% of Medicare beneficiaries aged ≥ 65 years old had their 
pneumococcal vaccine, as evidenced by the number of claims submitted to the Center for 
Medicaid Services (CDC, 2018). The data presented in Table 2 from the CDC (2018) shows a 
snapshot of Arizona’s vaccination rate of Medicare patients in comparison to other states. 
Comparing Arizona to 10 other representative states, Arizona ranks fourth highest in the number 
of claims for pneumonia vaccination. Although the number in Arizona is higher, in general this 
percentage still falls below the Healthy People 2020 goal of a 90% vaccination rate.  
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TABLE 2. Proportion of Medicare beneficiaries aged ≥ 65 years old with claims submitted for 
pneumococcal vaccination, by state, United States, September 2017. A sample of 10 states. 
 
 
Source: CDC, 2018 
One reason patients cite regarding why they were not immunized is the lack of provider’s 
recommendation on vaccination (Schneeberg et al., 2014). In order to attain the goal of 
increasing vaccinations rates, it is essential that providers were given the necessary tools to be 
effective in their job. Furthermore, for a change to sustain, a coordinated, multipronged 
adaptable change was required (Zimmerman, 2017). The Community Preventative Services Task 
Force (CPSTF) conducted a comprehensive literature review to determine ways to increase 
immunization uptake. Based on this study, increasing vaccinations included coordinated efforts 
and behavior changes from staff, patients and providers (CPSTF, 2014). The use of the Four 
Pillars Immunization Toolkit facilitated and supported the process in enhancing the vaccination 
uptake. The toolkit is a product that underwent years of research on the barriers and facilitators 
both from a patient and provider perspective (Zimmerman, 2017). 
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Purpose 
The twofold purpose of this DNP project was to identify barriers faced by regional 
Arizona providers with respect to recommending appropriate pneumonia vaccines for patients 65 
and older; and to increase pneumococcal vaccination rates for patients 65 and older in a single 
Arizona retail clinic by implementing the Four Pillars Immunization Toolkit. 
To implement this toolkit, one clinic was identified to conduct this project and the Four 
Pillars on Immunization Toolkit was utilized. This project was done in coordination with the 
Department Head of Education of the Little Clinic and the Regional Director of Nursing services 
for Arizona.  
Study Questions 
The study questions for this quality improvement project aimed at answering the 
following: 
1. Among Arizona regional providers in retail health clinic settings, what was the baseline 
knowledge and perception of barriers to pneumococcal vaccination of the providers? 
2. What was the vaccination rate among eligible patients throughout four weeks of Four 
Pillars Immunization Toolkit implementation? 
Synthesis of Evidence  
Framework: The Stetler Model 
The Stetler model (Stetler, 1994) was used as a vehicle to guide this project. This model, 
founded in 1976, is based on the principle of translating research into practice and could be used 
in an individual or group practice. Initially, the model did not have any basis in research, so it 
was focused on testing hypotheses. Since then, Stetler revised the model three times (1976, 1994, 
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2001), and it has been used in countless research studies on both the practitioner and 
organizational level. The current version of the model guides practitioners in assessing how 
research findings can be utilized in practice. The concept of the Stetler model is twofold: the 
translation of research into practice and the use of evidenced-based research to inform practice 
(National Collaborating Centre for Methods and Tools, 2010; Stetler, 2001). Regarding 
immunization, the decision of a patient to be immunized is dependent on the healthcare provider 
recommendation (Physician Weekly, 2015). 
Model concepts as described by Stetler (2001) are composed of the following assumptions: 
1. The formal organization may or may not be involved in an individual’s research 
utilization. 
2. Utilization may be instrumental, conceptual and symbolic.  
3. Other types of evidence and non-research related information is likely to be combined 
with research findings to facilitate decision-making or problem solving. 
4. Internal and external factors can influence an individual or a group’s view and use of 
evidence. 
5. Research and evaluation provide us with probabilistic information, not absolutes. 
6. Lack of knowledge and skills about research utilization and evidenced-based practice 
(EBP) can inhibit appropriate effective use. 
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FIGURE 2. Stetler model, steps in research utilization to facilitate EBP. (Adapted from Stetler, C. 
2001) 
Phase I Preparation 
Stetler (2001) described this phase as the phase where an individual practitioner identifies 
an issue (Figure 2). Included in this phase is the purpose, context, and research evidence (Figure 
2). Activities included in this phase are identifying key stakeholders and consideration of other 
factors that can influence the research, which can be described as external or internal factors. For 
this DNP project, the pressing issue that the author identified was the low rate of pneumococcal 
vaccination among the adult population ages 65 years and older. The Healthy People 2020 goal 
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for pneumococcal vaccination is set at 90%. Currently, there is a nationwide attention on adult 
immunization as the vaccination rates for adults are substantially below the national goal (Tan, 
2015). 
The stakeholders for this study were identified as the following: Regional Director for the 
Little Clinic, Education Director for the Little Clinic, Providers and Patient Care Technicians. 
One factor that may affect this study is the setting of this project. Unlike primary care offices, the 
retail-based clinic is a walk-in clinic. The provider might not be familiar with the patients as 
compared to a primary care office, and time might be a factor to consider in this setting. 
Phase II Validation 
The second phase of this model investigates the quality of existing evidence within the 
literature (Stetler, 2001). Currently, the literature has many resources on the use of Pneumovax 
23 (PPSV23) and Prevnar 13 (PCV13). The pieces of evidence provided were randomized 
controlled trials, systematic reviews, and meta-analyses on vaccine effectiveness. These pieces of 
evidence showed vaccine effectiveness of pneumococcal vaccines. One of the many examples is 
the Community-Acquired Pneumonia Trial in Adults on the use of PCV13 (CAPiTA). This trial 
is the largest randomized controlled trial in adults on the use of PCV13 against pneumonia. 
Based on the results of CAPiTA, the ACIP recommended routine sequential administration of 
PCV13 and PPSV23 in September 2014 (Isturiz & Webber, 2015). 
Phase III Comparative Evaluation and Decision Making 
Stetler (2001) describes this phase as a comparative evaluation and decision-making 
phase. Included in this phase are four criteria to determine if the research can be applied to the 
practice. The first criterion is the synthesis of findings. Considering previous evidence presented 
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on the effectiveness of PPSV23 and PCV13 vaccines, the researcher concludes that it is 
advisable to promote the pneumococcal vaccination. The second criterion evaluates the degree of 
feasibility, including consideration of risk, resources, and readiness. The company where this 
project occurred advocates the use of evidenced -based practice; therefore, it is not hard to get 
the support of the management as the company advocates the development of projects that can 
improve the delivery of health care in this setting. The third and fourth criteria include 
comparing the evidence with the current practice. The clinic has the availability of the 
vaccinations; however, the uptake for the pneumonia vaccines remains lower and trails behind 
other vaccines. 
Phase IV Translation/Application 
Stetler (2001) describes this phase as the translation and application phase. It involves the 
implementation of the research findings, which can be formal or informal. One should also 
consider the level where this evidence will be implemented: individual or group. This phase also 
considers the formal dissemination, which can be delivered through strategies such as appointing 
vaccine champions, providing interactive education, or conducting educational outreach.  
Phase V Evaluation 
Stetler (2001) describes this phase as the evaluation phase. The clinician at this phase 
evaluates the findings and considers the direct use of the evidence. If the practitioner decides to 
make direct use of the evidence, there needs to be pilot testing with a small group of people to 
consider feasibility for a larger group of people. The project yielded a favorable result on 
immunization rates. The process can be presented to the management to integrate in the current 
practice. 
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Conceptual Terms 
The focus of this quality improvement (QI) project was to address the immunization 
status of patients 65 years and older who use retail health clinics in Arizona. Among the 
population 65 years and older, inherent in this population is the use of Medicare insurance. The 
Medicare insurance program created in 1965 is a federal health insurance program for people 
aged 65 or older. In 1972, the program was expanded to cover certain people with disabilities 
and people with end stage renal disease (U.S. Centers for Medicaid and Medicare Services, n.d.). 
The setting for the QI project is The Little Clinic, which is also being referred to as a retail health 
clinic because is it located inside retail stores like Kroger, Fry’s, JC, Dillon’s, King Scoopers and 
Kroger stores (locally known as Fry’s). The Little Clinic employs practitioners such as physician 
assistants or nurse practitioners. Open seven days a week, the clinic offers an alternative 
treatment to receive care outside the operating hours of primary care doctors, giving patients the 
benefits of ease of access and cost-effective methods for receiving care (Heath, 2017). There are 
approximately 215 Little Clinics across the United States. In Arizona alone, there are 16 clinics 
located across Arizona (The Little Clinic, 2019). 
Currently, the Little Clinic is participating in the Merit-based Incentive Payment System 
(MIPS) quality measure data. MIPS was created to improve the health of all Americans by 
providing incentives to improve health outcomes (Manchikanti, Helm, Benyamin, & Hirsch, 
2016). One of the measures that the Little Clinic is using is the pneumococcal vaccination. 
The end goal of the QI project is the increase of pneumococcal vaccination for patients 
65 years old and older. There are two types of pneumococcal vaccination licensed for use in the 
United States by the Food Drug Administration (FDA): Pneumococcal conjugate vaccine known 
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as Prevnar 13 (PCV13) and 23 Pneumococcal polysaccharide vaccine known as Pneumovax 23 
(PPSV23). 
Prevnar 13 vaccine helps protect against 13 types of pneumococcal bacteria. It can 
prevent ear infections and pneumonia caused by those 13 types. This vaccine is given to children 
at ages 2 months, 4 months, 6 months, and 12 through 15 months. This vaccine is also indicated 
for older children and adults who are at increased risk for getting pneumococcal disease. For 
adults who need the vaccine, it is only given once (CDC, 2017). Prevnar 13 is a pneumococcal 
conjugate vaccine; conjugate refers to the type of vaccine that joins a protein to the part bacteria 
(CDC, 2017). Pneumovax 23 protects against serious infections caused by 23 types of 
pneumococcal bacteria. This vaccine is given as a single dose or sometimes includes one or two 
additional doses for people with a particular chronic medical condition. It is approved to be 
administered to people aged 2 years and older and 50 years of age and older who are at increased 
risk for pneumococcal disease (CDC, 2017). Pneumovax 23 is a pneumococcal polysaccharide 
vaccine; polysaccharide refers to the type of vaccine that mimics the appearance of certain 
bacteria (CDC, 2018). 
The Four Pillars Immunization Toolkit is an approach to adult immunization that utilizes 
four strategies. Developed by the University of Pittsburg, this strategy includes a step-by-step 
guide in delivering vaccination in an outpatient setting. The four strategies included in this 
approach are called pillars. Pillar 1 consists of offering convenient vaccine locations. Pillar 2 
consists of conveying to patients the importance of the vaccine and the availability of the 
vaccine. Pillar 3 includes enhancing the way the clinic offers immunization and Pillar 4 is the 
motivation of the staff to engage in the vaccination practices through identifying a champion in 
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the clinic. Furthermore, the Four Pillars Immunization Toolkit includes identification of barriers 
to increasing vaccination and the importance of giving a vaccine that can prevent illnesses 
(University of Pittsburg, 2019). 
Literature Review 
With the aging population, the economic burden of pneumococcal infection continues to 
affect everyone. Vaccines are not used to prevent diseases only for young children, but also for 
adults who are at risk for illnesses, hospitalizations, and even vaccine-preventable deaths. 
Despite the efforts placed on adult immunization, the 90% adult immunization goal for Healthy 
People 2020 has not been realized. Current data shows that 40,000-50,000 die from vaccine-
preventable diseases every year (Terrie, 2019). Although vaccines have been proven to have an 
enormous positive impact on health, many do not adhere with vaccination recommendations 
(Tan, 2015). Several reasons were identified for low adherence, such as noncompliance of adults, 
giving the vaccine a low priority both by the patient and the provider, lack of information 
regarding a vaccine, fear and opposition of the vaccine, affordability, and hindrances such as 
access to vaccines and systemic barriers (Wick, 2013).  
To establish the efficacy of vaccines, understand barriers that affect successful 
vaccination programs, and provide ways to implement a vaccination program that can increase 
the vaccination rates of pneumonia vaccines, several literature searches were conducted using 
PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), EBSCOhost, 
and Google Scholar. The following keywords were utilized in searching the databases: 
pneumococcal vaccinations, PPSV23, PCV13, patients 65 years and older, vaccination barriers, 
and retail clinics. Inclusion criteria for articles are those that were published within the last five 
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years, limited to English, and discussed human subjects who were 65 years and older. Articles 
that did not meet the criteria on pneumonia vaccination were eliminated from the study. Nine 
articles were chosen for this study. The articles used in the review of evidence included a variety 
of research approaches: randomized controlled trials, systematic reviews and meta-analyses, 
surveys, mixed methods, and cross-sectional designs. 
A very recent study (McLaughlin et al., 2019) used a cross-sectional design to establish 
the demographics and characteristics of patients who were most unlikely to get the pneumonia 
vaccination. It also measured the proportion of adults who were vaccinated against PCV13 
following the recommendations of ACIP. Giving credence to the study, the sample population is 
a large population base composed of 8,133,847 participants gathered from office-based medical 
claims, pharmacy, and hospital-based charge master claim databases. The outcome of this study 
noted that there was increased uptake of PCV13 among patients 65 years old and older. The 
demographic characteristics of people with poor adherence to vaccine recommendations includes 
people from poor minority communities, rural areas, and with low educational attainment. These 
same populations are at increased risk for pneumococcal infection. This finding established the 
need for providers to offer vaccinations to these groups of people. 
Another cross-sectional study (Schneeberg et al., 2014) sought to understand the factors 
influencing pneumococcal vaccination among older adults in Canada. Inclusion criteria included 
living independently and requiring minimal support for activities of daily living in five cities in 
Canada. The findings noted that physicians’ knowledge of vaccination affects whether they 
recommend it to patients. The study also validated that a physicians’ recommendation is 
consistently found to be an independent predictor for pneumonia vaccination. Hence, it is 
   
27 
essential that providers be equipped with adequate knowledge on vaccinations in order to 
educate patients on their need for vaccination. This finding is consistent with the study by Hurley 
et al. (2018), which was an assessment survey conducted among physicians on the knowledge 
gaps and barriers in recommending pneumococcal vaccination. It was noted that 50% of the 
physicians were unclear about the current pneumococcal guideline. Additionally, about one- 
third or more gave an incorrect dosing interval of PCV13 and PPSV23. Without knowledge-
based recommendations, pneumococcal vaccination cannot be implemented. 
Studies by Falkenhorst et al. (2017) and Botten et al. (2015) established the efficacy of 
the Pneumovax 23 and Prevnar 13 vaccines. Falkenhorst et al. (2017) pooled 17 eligible studies 
for a systematic review and meta-analysis looking for the effectiveness of Pneumovax 23. In four 
clinical trials, the vaccine effectiveness was 73%, while in three cohort studies vaccine 
effectiveness was at 45%, and in three case-control studies, vaccine effectiveness was at 59%. 
Overall, the meta-analysis revealed significant vaccine effectiveness of Pneumovax 23 against 
invasive pneumococcal disease and pneumococcal pneumonia in the elderly. 
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) study on 
the prevention of adult pneumococcal pneumonia with PCV13 (Bonten et al., 2015) was a 
randomized controlled trial of adults > 65 years of age. This study found statistically significant 
vaccine efficacy for first episodes of vaccine-type community-acquired pneumonia (46%), 
nonbacteremic/noninvasive vaccine type (45%), and vaccine-type invasive pneumococcal 
disease (75%). This study also reviewed the safety profile of Prevnar 13 showing that Prevnar 13 
is safe to use and has a well-established safety profile. 
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The literature search revealed there is a gap in the use of retail clinics to administer 
vaccinations. Retail clinics are scattered across the United States and are located in easily 
accessible areas with convenient extended hours. Despite the increased accessibility, few studies 
examined vaccination practices in the retail health clinics. Uscher-Pines et al. (2012) conducted a 
qualitative study on retail clinics as a venue to promote and administer vaccinations. The study 
sample was the three largest retail clinics in the country: Minute Clinic, Take Care Clinic and 
The Little Clinic. Across these three clinics, there were 8.9 million visits with 1.8 million 
influenza vaccinations given and 59,849 pneumococcal vaccinations administered from 2007-
2009. In comparing the yearly data, results reveal a yearly increase in the vaccination rates at 
39.9%, 36.4% and 42%. This data shows that the retail-based health clinics can be an avenue to 
capture immunizations among adults; however, providers have to be intentional to capture this 
during the visit (Uscher-Pines et al., 2012). The study is consistent with another study of a retail 
clinic by Duong (2016) examining a vaccination PCV13 protocol in the Palomar retail clinic. A 
total of 155 patients were deemed eligible for the study. This descriptive study utilized the 
Proves Discrepancy Evaluation Model. The providers were educated on the need for pneumonia 
vaccination. Providers increased their vaccine recommendations, which resulted in increased 
vaccination of the patients. In the three months that the researcher implemented the study, there 
was an increase in pneumonia vaccination to 2.5%, 20.9% and 14.3% from the baseline. Overall, 
the outcome of the study showed increased vaccination rates after education of providers on the 
pneumonia vaccine. 
There were various studies conducted on the use of the Four Pillars Immunization 
Toolkit. A randomized control study conducted by Zimmerman et al. (2017), on the use of the 
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toolkit to increase pneumococcal vaccination for older adults showed significant improvement 
for 23-valent pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal conjugate 
vaccine .This study identified 25 primary care practices with a cohort of 18,702 patients 65 years 
and older with a mean age of 74.2 
METHODS 
Research Questions 
This QI project consisted firstly of assessing the baseline knowledge of Arizona regional 
providers about pneumococcal vaccinations and on barriers to pneumococcal vaccination. The 
second part of the study was the utilization of the Four Pillars on Immunization Toolkit to 
increase pneumonia vaccination rates in that same setting. 
Design 
A descriptive cross-sectional study was conducted in the form of a survey to assess 
baseline knowledge and to identify perceived barriers to vaccine administration among 
providers. The survey questionnaire was patterned after another survey (Hurley et al., 2018) 
developed in coordination with the CDC. In this survey, each provider was given a series of 
seven case scenarios. The scenarios were created to determine the knowledge of the providers 
based on the ACIP recommendations. In addition, a series of five questions were developed in 
coordination with a clinical expert to assess the providers’ perceptions regarding barriers in 
giving vaccines. In order to address the second study question, a prospective observational study 
was conducted during four weeks of Four Pillars Immunization Toolkit implementation in one of 
the retail clinic locations in Arizona. 
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Ethical Considerations 
Before the implementation of this project, an Institutional Review Board approval 
through the University of Arizona (IRB) was obtained (Appendix A). The Director of Education 
for the retail clinic also approved the project before the implementation. Prior to the survey, 
participating providers gave their consent. Participation was voluntary, and no incentives were 
offered. Anonymity and confidentiality were assured to participants. The participants could stop 
at any time during the survey without any consequences. The data gathered for this project 
include de-identified data on how many patients 65 years old and older presented to the clinic, 
how many had immunization in the past and how many were given the immunization. 
For the Four Pillars on Immunization Toolkit implementation, one site was chosen for the 
implementation of this project. This clinic site consisted of four full time staff members. All 
participants gave their consent before the implementation of the project. The data gathered for 
this part of the project included identified data on how many patients who were 65 years and 
older presented to the clinic, how many had the immunization in the past and how many patients 
were given the immunization. 
Setting and Participants 
The data for the survey were collected from healthcare providers working for retail health 
care clinics in Arizona. The retail clinics were located inside grocery stores, which were owned 
and operated by a corporation. There were 16 clinics in different locations and each clinic was 
staffed with two full-time providers along with per diem or float providers. The providers were 
either nurse practitioners or physician assistants. Two nurse practitioners who were designated as 
Regional Clinical Directors oversaw the Arizona retail clinics.  
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The inclusion criteria for the survey included (a) nurse practitioners or physician 
assistants (b) working and providing treatment to patients seen at the retail location. A survey 
link was sent to potential participants through their work email. Two survey reminders were also 
sent, one at the end of the first week and another at the end of the second week. Participants were 
assured of confidentiality and anonymity. There were no identifying data obtained and only 
aggregate data was shared. 
The second part of the project was the utilization of the Four Pillars on Immunization 
Toolkit to increase the pneumococcal vaccination rates. One site was chosen for the 
implementation of this project. There were four full time staff in this location consisting of one 
nurse practitioner, one physician assistant and two patient care technicians (PCTs). The staff had 
a set work schedule and was divided into two teams. On some occasions when a full-time 
provider had taken time off from work, a float provider, who worked in different clinics, also 
worked in this location. This retail clinic is contracted with most of the commercial insurances 
including Medicare and Medicaid insurances. Most of the patients were walk-in customers; 
however, recently patients became able to schedule a same day visit ahead of time. While this 
clinic offered Pneumovax 23 and Prevnar 13 vaccinations, the uptake remained low. For 
example, last year from September 1, 2018 to October 1, 2018, the vaccination rates for these 
two vaccines was zero. 
Prior to the initiation of the project, coordination with the Head of Education for the retail 
health care clinic was done. After the approval of this project, the Regional Clinical Director was 
also informed and agreed to support the project. An IRB approval was obtained as well. The 
initiation of the project started with a lunch meeting with the staff of the chosen site. A 30-
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minute PowerPoint presentation was conducted with time for questions and answers provided. 
The project implementation ran from September 6, 2019 to October 6, 2019. A vaccination 
champion, who volunteered their services, were identified for each team. The vaccination 
champion was expected to make sure that there were available vaccines in the clinic and to track 
the quantity of immunizations given for each week. A tracking system was developed to 
document how many Prevnar 13 and Pneumovax 23 were given each week. 
As part of the toolkit implementation, a pneumococcal poster (Appendix E) was placed in 
strategic areas where patients could easily view it. When a 65-year-old patient checked in, the 
PCTs administered the questionnaires “What Vaccine Do I Need?” (Appendix F) and “Vaccine 
Information System” (Appendix G). Once the provider saw the patient, the provider discussed 
the vaccine with the patient and recorded in the Electronic Medical Record (EMR) if the patient 
had received the vaccine in the past and if the patient was interested in getting the vaccine. The 
providers were given the option to use the guides “Vaccine Schedule” (Appendix H) and 
“Vaccine Timing” (Appendix I) to help in the decision on what vaccine should be given. 
Data Collection 
For the question on assessing the baseline knowledge of the providers on the current 
pneumococcal vaccination, the data was collected through a survey. The survey consisted of 
questions including seven knowledge questions, three demographics questions, and five 
questions on perceived barriers to administering vaccinations. A Qualtrics link to the survey was 
sent to the participants’ work email (Appendix D). It was estimated that the survey took less than 
10 minutes. The participants gave their consent prior to the survey and could stop at any time. 
These data did not include any identifiers or, were de-identified prior to analysis. 
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The data collection for the assessment of vaccination rates during the toolkit 
implementation period involved coordinating with the Information Technology department from 
the headquarters. Patients 65 years and older were identified and past records were sought to 
determine vaccination history. All patients eligible to receive a pneumococcal vaccination based 
on Toolkit guidelines were included in analysis. 
Data Analysis 
Based on survey questions used in assessing the provider’s knowledge on baseline 
pneumococcal vaccination rate, data analysis including descriptive statistics in the form of 
counts and percentages was done using Qualtrics and Microsoft Excel 2016. The data are 
presented in a table and graph formats (Table 4). The data for vaccination rates during the 
utilization of the toolkit are presented in a table and graph formats (Table 5 & 6). 
RESULTS 
Sample Demographics 
The survey was sent to 44 nurse practitioner and physician assistants. Out of the total 44 
participants, 36 participants completed the demographic survey. Most providers had 0 to 4 years 
of experience and family practice experience. Table 3 shows the demographic characteristics of 
the participants. 
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TABLE 3. Self-reported demographic characteristics of the participants. 
Demographic Characteristics Category % n=36 
Gender Male   5 (14%) 
 Female 31 (86%) 
Years in Practice 0-4 17 (47%) 
 5-10   6 (17%) 
 11-15   6 (17%) 
  15    7 (19%) 
Experience in Other Specialty* Family Practice 24 (67%) 
 Urgent Care/ER 11 (31%) 
 Others   8 (22%) 
*Specialty categories are not mutually exclusive, and thus do not total 36 (100%) 
Provider Knowledge of Adult Pneumococcal Vaccine 
The providers were given a series of questions to determine their baseline knowledge of 
pneumonia vaccination. Out of the 36 providers who completed the demographic survey, 33 
providers answered the knowledge and perception question. The questions were presented with a 
multiple-choice answer. One of the options given was the “I need to look this up” answer. The 
data analysis shows that 81% of providers were able to identify which vaccine is to be 
administered first to patients ≥ 65 years old (Table 4). The second-highest score obtained was for 
the dosing interval between Prevnar 13 and Pneumovax 23 in patients ≥ 65 years old with 79% 
of the providers answering correctly. Regarding patients under age 65 with a qualifying 
condition, only 15% knew the correct dosing interval between PCV13 and PPSV23, which was 
also the lowest correct score on the knowledge survey. For this question, 61% chose incorrect 
responses rather than choosing option of “I need to look this up.” Suggesting confidence in their 
current vaccination knowledge even if incorrect. This data suggests that providers were most 
knowledgeable on the dosing interval in patients 65 years of age or older, but less knowledgeable 
on the dosing interval in patients less than 65 years old.  
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The second-lowest correct score (27%) was on the knowledge questions was which 
vaccine should be given to patients under the age of 65 with asthma, a chronic illness. In 
comparison, providers were most knowledgeable of which vaccine to give to patients 65 years 
old or older, who have a chronic illness. 
The question garnering the highest percentage of responses where provider would need to 
research the answer was on the dosing interval for Pneumovax 23 for patients ≥ aged 65 who 
received a previous dose of the same prior to age 65. Some 30% of the providers opted “I would 
need to look this up” and 33% chose incorrect responses, so although providers were aware of 
the first vaccine that needs to be given to patients ≥ age 65, providers were not completely 
knowledgeable regarding PPSV23 dosing regimens affecting this age group. 
In general, the mean score for the correct responses was 44.42, while the mean score for 
incorrect responses was 28.28. These means indicate that providers are knowledgeable on the 
topic to some degree, but a knowledge gap still exists. 
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TABLE 4. Number of participants answering the knowledge question 
Table 2. Number of Participants Answering The Knowledge Question: Correct ,Incorrect and Need to 
Look up 
 
Knowledge Concept  Correct Incorrect Need to look up 
    
 
Dosing Interval for PPSV 23 when a 
patient received PPSV23   at <65. 
When is the next due PPSV 23 due? 
(Chronic heart disease) 
 
12 11 10 
In patients with qualifying 
condition, what is the interval 
dosing between the PCV 13 and 
PPSV 23? (Cochlear Implant) 
 
5 20 8 
Dosing Interval between PCV 13 
and PPSV 23 in a 67-year-old 
patient (HTN needed refill) 
 
26 4 3 
Which pneumonia vaccine should 
be given first to adults ≥ 65? 
(Annual Wellness) 
 
26 3 3 
What vaccine is needed for a 24-
year -old patient?  (Asthma Pt) 
 
9 16 8 
In 28-year-old patients with 
qualifying condition who received 
PPSV 23 a year ago, what vaccine 
does she need? (HIV) 
 
20 9 4 
What pneumonia vaccine should be 
received first in a 42 -year-old 
patients with qualifying condition? 
(Nephrotic Syndrome) 
 
14 10 9 
PPSV (Pneumovax 23) 
PCV13(Prevnar 13 
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Perception of Barriers 
Data analysis on the barriers to giving pneumonia vaccines to patients 65 years old and 
older showed that participants felt that this is not a significant barrier (Figure 3). Most of the 
participants were aware of what vaccines were needed for patients age 65 and older with a 
percentage of 67% (about 22 participants). However, about 6% (2 participants) answered the 
question that major barriers exist. This data shows that many of the providers understand what 
vaccines are needed for patients over the age of 65. This data has linear relationships with the 
knowledge question on what vaccine should be given to patients 65 years and older. Because 
providers were knowledgeable, 81% got the correct answer; the providers therefore do not 
consider any barrier in giving immunization to this age group. 
Level of Severity 
The data showed that the question targeting the level of severity warranting Pneumovax 
23 was distributed among the different categories (Figure 3). About 38% (12 participants) 
answered that this is not a barrier. However, almost the same number of participants, 34% (11 
participants), considered this as a minor barrier. About 22% (7 participants) answered this 
question as a moderate barrier. Very few providers (6%) considered this as a major barrier. This 
category indicates that the participant's perception varies in this category. 
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Dosing intervals between Prevnar 13 and Pnuemovax 23 ≥ 65 years old. Data 
analysis indicated most of the providers at 63% or 20 participants (Figure 3) indicated that they 
do not consider the dosing interval between Prevnar 13 and Pneumovax 23 as a barrier. Two 
participants consider this as a major barrier. There were 16% or five participants who considers 
this as either a moderate or a minor barrier. In comparing this to the knowledge on the 67-year-
old patient with hypertension who needed medication refill, the participants also scored 79% or 
26 providers answered this category correctly. This score was one of the highest scores obtained 
among all the knowledge questions confirming that participants are comfortable and 
knowledgeable in this category. 
Unaware Patients and Vaccines 
This analysis indicates patients are unaware of what previous vaccines they received; the 
unawareness will create a barrier in receiving the next vaccine (Figure 3). About 42%, or 13 
participants, considered this as a major barrier. Among all the perceived barriers, this condition 
obtained the highest rating as a major barrier in giving or recommending the pneumonia 
vaccination. This data indicated the general findings on the perception of barriers show that 
unawareness of what vaccine the patient had is a significant barrier in giving the pneumonia 
vaccine in a retail setting. 
Barrier perception on medical condition that warrants both Prevnar 13 and 
Pneumovax 23 for patients 65 years and under. Figure 3 shows that 33% or 11 of the 
respondents consider this category on medical conditions warranting both Pneumovax 23 and 
Prevnar 13 as a moderate barrier, while 30% or 10 of the participants consider this as a minor 
barrier. There were 24% or eight of the providers who considered this category not as a barrier, 
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while 9% or three of the participants considered this as a major barrier. One of the participants 
selected the answer of not sure. 
In general, the data indicated that the participants’ responses varied, but indicated that 
knowledge deficits exist. 
 
FIGURE 3. Summary on barrier perception. 
Data on Utilizing the Four Pillars on Immunization Toolkit 
The Four Pillars on Immunization toolkit was utilized in one of the clinics in Arizona 
Region. This toolkit was implemented from September 6, 2019 to October 6, 2019. Data were 
gathered to determine if using the toolkit will result in an increase in vaccination rate for 
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pneumonia vaccine among patients 65 years and older. The data analysis was for a one-month 
period from September 6, 2019 to October 6, 2019 (Table 5). These patients were qualified to 
receive either Prevnar 13 or Pneumovax 23. The total number of patients seen within this period 
was 546 patients. Out of this total number of patients, 22 patients were older or equal to 65 years 
of age as a patient. Some 20 patients were eligible for the pneumonia vaccine. The rest of the 
patients’ ages were below 65 years old. 
TABLE 5. Summary of eligible patients seen and received vaccination. 
Week Total Pts Seen Patients ≥65 Number Eligible Number Vaccinated 
Week 1 144 6 6 0 
Week 2 88 1 1 0 
Week 3 177 8 7 1 
Week 4 197 7 6 1 
Uptake on Prevnar 13 and Pneumovax 23 
The data shows 22 patients were older than 65 years of age who presented to the clinic 
during the study period (Table 6). The length of the study was one month. Of the 22 patients, two 
patients in week 1 and week 2 already received their immunization series somewhere else, thus, 
making the total eligible patients seen in the clinic at 20. During the study period, one patient 
was vaccinated with Prevnar 1, and one patient was vaccinated with Pneumovax 23. 
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DISCUSSION 
There are two parts to this project. The first part of the project was to assess the 
providers’ baseline knowledge and perception of barriers in giving pneumococcal vaccinations. 
The second part was to implement the toolkit in providing pneumococcal vaccinations to patients 
age 65 and older in a retail clinic setting.  
Knowledge and Perception 
There were several knowledge gaps noted from responses to the knowledge 
questionnaire. Most participants, however, were able to answer correctly the question of which is 
the first immunization to be given to patients who were ≥65 years old with no history of prior 
vaccination. The provider’s knowledge in this area could have been related to media campaigns 
on immunization targeting seniors. Most of the providers also answered the dosing interval 
between Pneumovax 23 and PCV13 for patients ≥ 65 years old correctly. In comparison, there 
seems to be a knowledge gap regarding the dosing interval between Pneumovax 23 and Prevnar 
13 for patients under age 65. Only 15% of the participants answered this question correctly. In 
addition, 48% of the participants answered incorrectly the question about what type of vaccine 
an asthmatic patient 65 years old and below old should receive. Only 36% of the providers knew 
the correct dosing interval when Pneumovax 23 is given to patients ≥ 65 years old after a prior 
dose before age 65, revealing another knowledge gap. In general, the highest scores obtained 
were for those vaccines targeting the seniors, but a lowered score noted to those vaccines 
targeting patients below 65 years old. The results of this survey will be sent to the management 
with suggestions on interventions to address the issue. 
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The perception on barriers to giving pneumococcal vaccination in a retail health setting is 
varied. The highest score obtained from the data set (42%) in this section was the difficulty 
determining what vaccines the patients previously received. Patients are unaware of what 
previous vaccine they had received. The lack of record keeping for pneumonia vaccine can be 
attributed to this scenario of patients getting their pneumonia vaccines from different providers 
ranging from their doctor's office, to retail clinics, or local pharmacies. When a patient does not 
have a record of their vaccine, it is difficult to determine which immunization to give. Adult 
patients who do not have any immunization records that they can show to the provider is a 
missed opportunity to vaccinate. 
Several implications can be made from this study, for example, the need to address the 
knowledge deficits of the providers. Some of the strategies that can be implemented to address 
this need is the provision of the vaccine timing guide from the CDC be given to each clinic. In 
addition, an education campaign targeting pneumonia vaccinations should be created through a 
platform such as the HealthStream. The HealthStream is the platform the Little Clinic uses for 
education dissemination. 
Another approach that might help the providers in the decision-making process of what 
vaccine to give is the creation of a Clinical Support Decision System (CDSS) within the 
Electronic Medical Record (EMR) to identify adult patients needing pneumonia vaccination. 
Rather than relying on the knowledge of the provider, the CDSS can help providers make 
decisions. 
There is also a need to create a Nationwide Adult Vaccination System that providers can 
access to determine what vaccine the patient has already received. This strategy would most 
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likely address the highest-rated barrier on patients being unaware of what vaccine they already 
received. This strategy will take longer to implement. A short-term solution to utilize is the 
vaccine passbook that can be given to patients. This vaccine passbook will contain immunization 
records that patients can bring during their appointments. 
On Toolkit Utilization 
Data shows immunization coverage for pneumonia vaccination is below the goal of 
Healthy People 2020 (CDC, 2015). The national target for Healthy People 2020 for pneumonia 
vaccination is at 90%. The actual vaccination rates for patients with high-risk conditions between 
19-64 years old is at 21% and the national percentage for pneumonia vaccine for adults greater 
than or equal to 65 years and older is at 60% (CDC, 2015). To see if a retail clinic can be used as 
an avenue to increase the pneumococcal vaccination rate, the Four Pillars on Immunization 
Toolkit project was utilized and implemented in a retail clinic setting. The findings showed when 
compared to last year's data (2018) on the pneumonia vaccination rate at the 91st and Olive Little 
Clinic; there is an increase of 10% pneumonia vaccination rate with the utilization of the Four 
Pillars on Immunization Toolkit. 
Retail health clinics can be avenues to close the gap in vaccination rates through the 
growing number of retail clinics across the country. These clinics provide convenient locations, 
easy access to care, convenient hours, and walk-in visits with prices that are transparent (Kaiisi, 
2015). In addition, to be competitive at the local market, scheduled appointments are utilized.  
The missed vaccination data where patients were unaware of what vaccine they had in the 
past or did not get their pneumonia immunization because of no vaccine record represents a 
significant opportunity to provide patients with a vital vaccine. CDC (2016) guidelines about 
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revaccination for those over the age of 65 who are unaware of what vaccine they had in the past 
can be summarized with the following questions: Has the person been vaccinated previously? No 
or unsure answer, give the vaccine.  
On the first two weeks of the project implementation, there were no vaccines given as 
this was expected due to a learning curve for the providers. In the third and fourth weeks, there 
were 85.7% and 87.5% eligible patients who were identified and out of these eligible patients, 
two were vaccinated. These results most likely reflect the provider’s comfort level with the 
project. In addition, there was a slight increase in patients over or equal to 65 years of age who 
were seen in the clinic secondary to the availability of the influenza vaccine. 
There were several barriers that the providers discussed and mentioned during the period 
of this study. For example, the Electronic Medical Record (EMR) does not prompt providers to 
ask questions on immunization and at times due to the volume of patients, they often forget to 
ask or mention the pneumonia vaccine. Another issue reported by the providers was that of 
patients not knowing what vaccines they had in the past, which prompted the providers not to 
give or recommend a vaccine because insurance may not cover the service. This may lead to the 
patients paying out of their pockets. In addition, there was one occasion where the patient was 
ready to get the vaccine, however the clinic ran out of Prevnar 13. There was also an instance 
where a float provider who is not aware of the project worked in the clinic for just a single day.  
Another barrier that can be deduced from this project is the continued emphasis on acute 
illnesses versus preventative care. For the immunization vaccination rate to increase in this 
setting, there should be a continued effort to educate providers on preventative measures such as 
immunization practices. In addition, the Electronic Medical Record (EMR) should be enhanced 
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to prompt providers to ask immunization questions rather than rely solely on the providers to 
remember to ask the patients. While this project was conducted in a short period of time, with 
few patients getting vaccinated, it does support retail health clinics as avenues to increase 
Pneumonia vaccination rates as well as help achieve the Healthy People Goal 2020 and beyond.  
Limitations and Conclusion 
Knowledge of the provider and the perception of barriers to Pneumonia vaccination was 
generated from a small sample size. Out of the possible 44 participants, 36 submitted their 
demographic survey. The participants were healthcare providers located in Arizona. No other 
locations outside of Arizona were asked to participate in the study. In utilizing the toolkit to 
increase the immunization, large sample sizes would have given a basis to determine if similar 
results would have been reproduced in other regions. Another limitation was the perception of 
barriers in pneumococcal vaccination. While content experts reviewed this, no previous analysis 
of the survey was done. In addition, the perceptions and knowledge of the providers may not be 
fully reproducible. 
Study strengths include the Merit-based Incentive Payment System (MIPS), in which this 
retail clinic currently participates. The MIPS utilizes a data reporting system. Providers are 
required to document previous pneumonia vaccinations. This action compels the providers to 
inquire about pneumonia vaccine when a patient presents to the clinic. Although, the provider 
mentioned that although the documentation for the MIPS is required at times this is not always 
done. Significant findings included the knowledge gap of the providers and the barriers that the 
providers faced in recommending pneumonia vaccination. 
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The Four Pillars in Immunization Toolkit resulted in an increase in the vaccination rate 
when compared to the data from 2018. This can imply that though retail clinics are a newer form 
of health care delivery, vaccinations delivery can be employed in this setting. These findings 
validate how retail clinics could be used as avenues to help reach local and national 
immunization goals. The results of this study de-identified data will be shared with management. 
The utilization of the Four Pillars on Immunization Toolkit also utilized a small sample 
size. Out of all the 16 total clinics, only one clinic was utilized for the study. Most of the visits in 
that location were patients below 65 years of age. The timing of the project is also taken into 
consideration. The clinic area is in the locality where older people are referred to as “snowbirds” 
and visit during the winter. This project was conducted at the time when it was too early for the 
“snowbirds” to come to Arizona and was only for a short duration of time. The survey conducted 
in this study uncovered a knowledge gap with the pneumococcal vaccination among the retail 
health providers. This study also showed there were significant barriers that the providers were 
facing regarding recommending or administering the pneumonia vaccine. There are very limited 
studies involving retail clinics specifically covering the topic of vaccination. This study is unique 
in the sense that retail clinics are growing in numbers; however, few researches has been done on 
the delivery of healthcare through this avenue. As the retail clinics continue to grow and expand 
its services, providers working in this area must ensure that the knowledge is current with the 
practice guidelines. Furthermore, this study also incorporated a toolkit through immunization 
practices. This toolkit showed that retail health clinics can assist in improving vaccination rates. 
The information gathered in this study may be applied to other retail sites who conduct a 
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pneumonia vaccination educational program and provide valuable resources, which providers 
can utilize. 
 
   
48 
APPENDIX A: 
THE UNIVERSITY OF ARIZONA INSTITUTIONAL REVIEW BOARD APPROVAL 
LETTER 
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To the Little Clinic Healthcare Providers: 
 My name is Minnerva Carroz, MSN, FNP-C and I am a fellow retail clinic provider. I am 
currently completing my Doctor of Nursing Practice (DNP) degree at the University of Arizona. 
I am asking for your participation and assistance in my DNP project survey to assess the baseline 
pneumococcal vaccination knowledge in retail health care providers.  
 The current data on Pneumococcal vaccination rates for patients 65 years and older are way 
below the national goal, however retail clinics has been increasing in numbers. The retail clinics 
can be used as avenues to meet the Healthy People Goal for pneumonia vaccination. This survey 
will explore the needs and barriers of our providers in providing pneumococcal vaccinations as 
the retail clinic continue to expand beyond delivering acute care to providing preventative care. 
The purpose of this project is to assess provider baseline knowledge of pneumococcal 
vaccination in a retail setting. 
 There is a link for the online survey at the bottom of this email. This survey is estimated to take 
10 minutes to complete.  
 There are no expected risks to participate in this project. Only aggregate data will be presented 
in a summary format. Your participation is voluntary. There are no consequences if you choose 
not to participate or if you choose not to complete the survey. Your participation is confidential 
and no identifying information will be collected. 
 Please email any questions or concerns you have regarding this project to me, the primary 
investigator at Mcarroz@email.arizona.edu. You may also contact me directly at 623-565-7563. 
I will do my best to respond to questions and concerns within 24 hours. 
 By completing the survey, you are consenting to participate in this research project and agree to 
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APPENDIX C: 
RECRUITMENT LETTER UTILIZING THE FOUR PILLARS ON IMMUNIZATION 
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Increasing Pneumococcal Vaccination Rates Among 65 Year Old and Older Patients In A Retail 
Clinic Setting 
 by Minnerva Carroz 
 
The purpose of this project is to increase vaccination pneumococcal rates among 65 years old 
and older patients utilizing the Four Pillars on Immunization Toolkit. 
 
If you choose to take part in this project you will be asked to participate in the implementation of 
the toolkit. The toolkit involves making sure that pneumonia vaccines are available in the clinic, 
providing brochures, handouts to patients, asking about pneumonia vaccination status during the 
visit and the creation of a vaccination champion in the clinic. There are no foreseeable risks 




If you choose to participate in the project, your participation is voluntary and refusal to 
participate will involve no penalty or loss of benefits which you are otherwise entitled to. You 
may withdraw at any time from the project. In addition, you may skip any question that you 
choose not to answer. By participating, you do not give up any personal legal rights you may 
have as a participant. 
 
 
For any questions, concerns, or complaints about the project, you may call Minnerva Carroz, 
FNP-C at 623 565 7563 and email address at mcarroz@email.arizona.edu 
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Survey questions  
 
(Correct answers bolded and underlined) 
 
1. A 65-year-old, otherwise healthy woman with no history of prior pneumococcal 
vaccination, sees you for an Annual Wellness Visit. Which, if any, pneumococcal 
vaccine(s) should be administered at this visit? 
• PPSV23 
• PCV13  
• None 
 Both 
 I would need to look this up  
 
2. A 24-year-old man sees you for a routine office visit. He has asthma and has not 
previously received any pneumococcal vaccines. Which, if any, pneumococcal vaccine(s) 





 I would need to look this up 
 
3. A 28-year-old woman with HIV infection sees you for a routine visit. She received 1 
dose of PPSV23 one year ago. Which, if any, pneumococcal vaccine(s) should be 
administered at this visit? 
• PPSV23 
• PCV13  
• None 
 Both 
 I would need to look this up 
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4. A 42-year-old man with nephrotic syndrome sees you for a routine visit. He has not 
previously received any pneumococcal vaccines. Which, if any, pneumococcal vaccine(s) 





 I would need to look this up 
 
5. A 66-year-old man with chronic heart disease sees you for a routine visit. He received 1 
dose of PPSV23 at age 64. At what age, if at all, should he receive another dose of 
PPSV23? 
• Age 66 
• Age 67 
• Age 69 
• Age 75 
• I would need to look this up 
 
6. A 42-year-old man with cochlear implants sees you for a routine visit. He had received a 
PCV13 vaccine at his otolaryngologist’s office the day before. When should a PPSV23 
vaccine be administered? 
 Never. The patient does not need a PPSV23. 
 At least 8 weeks after the PCV13 vaccine 
 • At least 1 year after the PCV13 vaccine 
 At least 5 years after the PCV13 vaccine 
 I would need to look this up 
 
7. A 67-year-old man with hypertension presents for a medication refill. You notice he 
received a PCV13 vaccine 6 months ago, but has not received a PPSV23 vaccine. When 
should he receive the PPSV23 vaccine? 
 Never. He does not need a PPSV23. 
 Today 
 In 6 months 
 Five years after he received the PCV13 vaccine 
 I would need to look this up 
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BARRIER QUESIONS 
Do you consider the following as a barrier in recommending or giving the pneumonia vaccine 
to patients ? 
 
1. Understanding which Pneumococcal vaccines are needed by patients who are 65 years and 
older. 
 
☐Major Barrier ☐Moderate Barrier ☐ Minor Barrier ☐ Not a Barrier ☐ Not Sure 
 
2. Understanding the recommended time interval between the two vaccines (Prevnar 13 and 
Pnuemovax 23) to be administered to patients who are 65 years old and older. 
 
☐Major Barrier ☐Moderate Barrier ☐ Minor Barrier ☐ Not a Barrier ☐ Not Sure 
 
3. For patients who are under 65 years old with certain medical conditions, understanding 
what level of severity of medical condition warrants Pneumovax 23 vaccination. 
 
☐Major Barrier ☐Moderate Barrier ☐ Minor Barrier ☐ Not a Barrier ☐ Not Sure 
 
4. Patients are unaware of what kind of pnuemonia vaccine they had previously received. 
 
☐Major Barrier ☐Moderate Barrier ☐ Minor Barrier ☐ Not a Barrier ☐ Not Sure 
 
5. For patients under 65-years-old with certain medical , understanding the medication 
conditions that qualify a patient for both vaccines (Prevnar 13 and Pnuemovax 23) 
 
☐Major Barrier ☐Moderate Barrier ☐ Minor Barrier ☐ Not a Barrier ☐ Not Sure 
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Poster on Pneumococcal 
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APPENDIX F: 
WHAT VACCINE DO I NEED? 
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APPENDIX G: 
VACCINE INFORMATION STATEMENT 
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VACCINE INFORMATION STATEMENT 
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APPENDIX H: 
GUIDE FOR PROVIDERS 
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GUIDE FOR PROVIDERS 
 
 





   
70 
Vaccine Timing  
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